STIM2 and Werner syndrome: In research on the risk of TKI withdrawal syndrome, Berger et al. [159] obtained a significantly higher incidence of WS after discontinuation of 2G TKI than with imatinib by analyzing a cohort of 427 patients from EURO-SKI and STIM2 studies.